Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve ...
A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and ...
NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
Pfizer, BioNTech seek administrative review of 2 Moderna patents at heart of mRNA vaccine litigation
As Moderna’s COVID vaccine patent lawsuits wind their way through courts around the globe, Pfizer and BioNTech contend their rival is trying to monopolize the entire mRNA field. In the latest chapter ...
BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech’s capabilities and proprietary technologies in mRNA ...
BioNTech SE ( ($BNTX) ) has provided an update. On December 18, 2025, BioNTech SE announced it had closed its acquisition of CureVac N.V., ...
Health officials say it’s time for most Americans to get another booster dose—this time, with a new Omicron-specific shot made by either Pfizer-BioNTech (for people 12 and older) or Moderna (for ...
The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback